Literature DB >> 16506414

Behavioral methods in cannabinoid research.

Ester Fride1, Alex Perchuk, F Scott Hall, George R Uhl, Emmanuel S Onaivi.   

Abstract

In the absence of any specific behavioral assay for cannabinoids or endocannabinoids, a cannabinoid-induced profile in a series of four in vivo assays in mice is most commonly used to assess a specific cannabinoid activity at the behavioral level. Thus, when a given compound produces motor depression in an open field, catalepsy on an elevated ring, analgesia on a hot plate, as well as hypothermia, cannabinoid CB1 receptor activation is assumed, although exceptions are possible. The full cannabinoid profile, however, includes for example ataxia in dogs and discrimination learning in rats. In view of (1) the addictive/reward potential of cannabis and the cannabinoids and (2) the multiple roles of the endocannabinoid physiological control system (EPCS) in behavioral functions, including memory, emotionality, and feeding, a number of behavioral techniques have been used to assess the effects of cannabinoids in these functions. In this chapter we will describe the tetrad of cannabinoid-induced effects as well as a series of behavioral assays used in the behavioral pharmacology of marijuana-cannabinoid research. Since the EPCS plays an important role in the developing organism, methods used in the assessment of physical and behavioral development will also be discussed. The techniques include the tetrad, drug discrimination, self-stimulation and self-administration, conditioned place preference/aversion, the plus-maze, chronic mild stress (CMS), ultrasonic vocalizations, cognitive behaviors, and developmental assessment in mouse (and rat) pups.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16506414     DOI: 10.1385/1-59259-999-0:269

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  12 in total

1.  The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors.

Authors:  A Chicca; J Marazzi; J Gertsch
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

2.  Behavioral responses to acute and sub-chronic administration of the synthetic cannabinoid JWH-018 in adult mice prenatally exposed to corticosterone.

Authors:  Simone Macrì; Lara Lanuzza; Gustavo Merola; Chiara Ceci; Stefano Gentili; Antonella Valli; Teodora Macchia; Giovanni Laviola
Journal:  Neurotox Res       Date:  2013-01-08       Impact factor: 3.911

3.  Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development.

Authors:  Benjamin M Ford; Lirit N Franks; Sherrica Tai; William E Fantegrossi; Edward L Stahl; Michael D Berquist; Christian V Cabanlong; Catheryn D Wilson; Narsimha R Penthala; Peter A Crooks; Paul L Prather
Journal:  Pharmacol Res       Date:  2017-08-23       Impact factor: 7.658

4.  Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.

Authors:  Gerald T DeLong; Carl E Wolf; Alphonse Poklis; Aron H Lichtman
Journal:  Drug Alcohol Depend       Date:  2010-11-01       Impact factor: 4.492

5.  Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation.

Authors:  Tzu-Tang Wei; Mark Chandy; Masataka Nishiga; Angela Zhang; Kaavya Krishna Kumar; Dilip Thomas; Amit Manhas; Siyeon Rhee; Johanne Marie Justesen; Ian Y Chen; Hung-Ta Wo; Saereh Khanamiri; Johnson Y Yang; Frederick J Seidl; Noah Z Burns; Chun Liu; Nazish Sayed; Jiun-Jie Shie; Chih-Fan Yeh; Kai-Chien Yang; Edward Lau; Kara L Lynch; Manuel Rivas; Brian K Kobilka; Joseph C Wu
Journal:  Cell       Date:  2022-04-29       Impact factor: 66.850

6.  Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain.

Authors:  Arieh Moussaieff; Neta Rimmerman; Tatiana Bregman; Alex Straiker; Christian C Felder; Shai Shoham; Yoel Kashman; Susan M Huang; Hyosang Lee; Esther Shohami; Ken Mackie; Michael J Caterina; J Michael Walker; Ester Fride; Raphael Mechoulam
Journal:  FASEB J       Date:  2008-05-20       Impact factor: 5.191

7.  Dose-dependent teratogenicity of the synthetic cannabinoid CP-55,940 in mice.

Authors:  Marcoita T Gilbert; Kathleen K Sulik; Eric W Fish; Lorinda K Baker; Deborah B Dehart; Scott E Parnell
Journal:  Neurotoxicol Teratol       Date:  2015-12-18       Impact factor: 3.763

Review 8.  Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease.

Authors:  Debra A Kendall; Guillermo A Yudowski
Journal:  Front Cell Neurosci       Date:  2017-01-04       Impact factor: 5.505

9.  The Directive 2010/63/EU on animal experimentation may skew the conclusions of pharmacological and behavioural studies.

Authors:  Simone Macrì; Chiara Ceci; Luisa Altabella; Rossella Canese; Giovanni Laviola
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

10.  Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation.

Authors:  Daniel J Hermanson; Nolan D Hartley; Joyonna Gamble-George; Naoko Brown; Brian C Shonesy; Phillip J Kingsley; Roger J Colbran; Jeffrey Reese; Lawrence J Marnett; Sachin Patel
Journal:  Nat Neurosci       Date:  2013-08-04       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.